CL2023003491A1 - Derivados de triazina y su uso en el tratamiento del cáncer - Google Patents
Derivados de triazina y su uso en el tratamiento del cáncerInfo
- Publication number
- CL2023003491A1 CL2023003491A1 CL2023003491A CL2023003491A CL2023003491A1 CL 2023003491 A1 CL2023003491 A1 CL 2023003491A1 CL 2023003491 A CL2023003491 A CL 2023003491A CL 2023003491 A CL2023003491 A CL 2023003491A CL 2023003491 A1 CL2023003491 A1 CL 2023003491A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer treatment
- triazine derivatives
- compounds
- triazine
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21177660 | 2021-06-04 | ||
| EP21188639 | 2021-07-30 | ||
| EP21215875 | 2021-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003491A1 true CL2023003491A1 (es) | 2024-05-24 |
Family
ID=82115763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003491A CL2023003491A1 (es) | 2021-06-04 | 2023-11-23 | Derivados de triazina y su uso en el tratamiento del cáncer |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20240132471A1 (OSRAM) |
| EP (1) | EP4347571B1 (OSRAM) |
| JP (2) | JP7705963B2 (OSRAM) |
| KR (1) | KR20240019083A (OSRAM) |
| AR (1) | AR126053A1 (OSRAM) |
| AU (1) | AU2022287224A1 (OSRAM) |
| BR (1) | BR112023025318A2 (OSRAM) |
| CA (1) | CA3216026A1 (OSRAM) |
| CL (1) | CL2023003491A1 (OSRAM) |
| CO (1) | CO2023016212A2 (OSRAM) |
| CR (1) | CR20230566A (OSRAM) |
| IL (1) | IL307201A (OSRAM) |
| MX (1) | MX2023013998A (OSRAM) |
| PE (1) | PE20240928A1 (OSRAM) |
| TW (1) | TW202313577A (OSRAM) |
| WO (1) | WO2022253936A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| BR112023022451A2 (pt) * | 2021-04-28 | 2024-01-02 | Astellas Pharma Inc | Composto triazina substituído |
| BR112023025318A2 (pt) * | 2021-06-04 | 2024-02-27 | Hoffmann La Roche | Derivados de triazina e seu uso no tratamento do câncer |
| CA3246797A1 (en) * | 2022-01-07 | 2025-07-08 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and application thereof |
| US20260015353A1 (en) * | 2022-07-21 | 2026-01-15 | Hoffmann-La Roche Inc. | Novel compounds |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN121045190A (zh) * | 2022-11-04 | 2025-12-02 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| CR20250215A (es) * | 2022-12-07 | 2025-06-26 | Hoffmann La Roche | Compuestos novedosos como moduladores de la inhibición de nlrp3 |
| KR20250158072A (ko) * | 2023-03-20 | 2025-11-05 | 인실리코 메디신 아이피 리미티드 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
| KR20250162889A (ko) * | 2023-03-23 | 2025-11-19 | 청두 제니타르 바이오메디컬 테크놀로지 컴퍼니 리미티드 | 트리아진계 화합물 및 이의 용도 |
| TW202448448A (zh) * | 2023-04-19 | 2024-12-16 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| CR20250409A (es) * | 2023-04-19 | 2025-10-30 | Hoffmann La Roche | Derivados de oxazolo[4,5-b]pirazina y oxazolo[4,5-b]piridina como inhibidores de nlpr3 para el tratamiento de, por ejemplo, enfermedades inflamatoria |
| EP4719599A1 (en) | 2023-06-02 | 2026-04-08 | Merck Sharp & Dohme LLC | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
| CN121586712A (zh) * | 2023-07-28 | 2026-02-27 | 豪夫迈·罗氏有限公司 | 新颖化合物 |
| KR20250030934A (ko) * | 2023-08-25 | 2025-03-05 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025252772A1 (en) * | 2024-06-06 | 2025-12-11 | F. Hoffmann-La Roche Ag | Triazine derivatives |
| WO2026046981A1 (en) | 2024-08-28 | 2026-03-05 | F. Hoffmann-La Roche Ag | Solid forms of 5-[3-[[(3r)-1-ethyl-3-piperidyl]amino]-5-methyl-1,2,4-triazin-6-yl]-2,3- dihydrobenzofuran-4-ol |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102636383B1 (ko) * | 2017-08-04 | 2024-02-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| TW201910316A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| PE20210050A1 (es) | 2017-11-09 | 2021-01-08 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida |
| AU2019243048A1 (en) * | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| US12168012B2 (en) | 2018-07-25 | 2024-12-17 | Novartis Ag | NLRP3 inflammasome inhibitors |
| CN119320388A (zh) * | 2019-02-04 | 2025-01-17 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| JP7843705B2 (ja) | 2020-01-22 | 2026-04-10 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 |
| ES3064621T3 (en) | 2020-03-27 | 2026-04-27 | Tenvie Therapeutics Inc | Substituted pyridazine compound |
| US20240391895A1 (en) | 2020-12-25 | 2024-11-28 | Tuojie Biotech (Shanghai) Co., Ltd. | Pyridazine-containing compound and medicinal use thereof |
| WO2022166890A1 (zh) | 2021-02-08 | 2022-08-11 | 南京明德新药研发有限公司 | 取代的哒嗪苯酚类衍生物 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| BR112023022451A2 (pt) | 2021-04-28 | 2024-01-02 | Astellas Pharma Inc | Composto triazina substituído |
| BR112023025318A2 (pt) * | 2021-06-04 | 2024-02-27 | Hoffmann La Roche | Derivados de triazina e seu uso no tratamento do câncer |
| US20240294542A1 (en) | 2021-06-05 | 2024-09-05 | Transthera Sciences (Nanjing), Inc. | Nlrp3 inflammasome inhibitor and application thereof |
| HRP20251513T1 (hr) | 2021-07-02 | 2026-01-02 | Astrazeneca Ab | Inhibitori inflamasoma nlrp3 |
| WO2023028536A1 (en) | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
| WO2023066377A1 (zh) | 2021-10-22 | 2023-04-27 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
| CA3246797A1 (en) | 2022-01-07 | 2025-07-08 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and application thereof |
| IL315842A (en) | 2022-03-25 | 2024-11-01 | Ventus Therapeutics U S Inc | Pyrido-[4,3-D]pyridazine amine derivatives are useful as NLRP3 derivatives |
| TW202432551A (zh) | 2022-10-26 | 2024-08-16 | 日商安斯泰來製藥股份有限公司 | 稠環嗒嗪衍生物 |
| CN115621720A (zh) * | 2022-10-27 | 2023-01-17 | 永道射频技术股份有限公司 | 一种应用于rfid读写器的全息超材料阵列天线 |
| CN121045190A (zh) | 2022-11-04 | 2025-12-02 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| JP2026503239A (ja) | 2022-12-28 | 2026-01-28 | アストラゼネカ・アクチエボラーグ | Ｎｌｒｐ３インフラマソーム阻害剤 |
| CN120435466A (zh) | 2023-02-17 | 2025-08-05 | 成都赜灵生物医药科技有限公司 | 六元氮杂环类化合物及其用途 |
-
2022
- 2022-06-02 BR BR112023025318A patent/BR112023025318A2/pt unknown
- 2022-06-02 IL IL307201A patent/IL307201A/en unknown
- 2022-06-02 EP EP22731614.8A patent/EP4347571B1/en active Active
- 2022-06-02 JP JP2023572751A patent/JP7705963B2/ja active Active
- 2022-06-02 MX MX2023013998A patent/MX2023013998A/es unknown
- 2022-06-02 KR KR1020237039328A patent/KR20240019083A/ko active Pending
- 2022-06-02 CR CR20230566A patent/CR20230566A/es unknown
- 2022-06-02 CA CA3216026A patent/CA3216026A1/en active Pending
- 2022-06-02 AR ARP220101456A patent/AR126053A1/es unknown
- 2022-06-02 TW TW111120574A patent/TW202313577A/zh unknown
- 2022-06-02 WO PCT/EP2022/064995 patent/WO2022253936A1/en not_active Ceased
- 2022-06-02 PE PE2023003133A patent/PE20240928A1/es unknown
- 2022-06-02 AU AU2022287224A patent/AU2022287224A1/en active Pending
-
2023
- 2023-11-23 CL CL2023003491A patent/CL2023003491A1/es unknown
- 2023-11-29 CO CONC2023/0016212A patent/CO2023016212A2/es unknown
- 2023-11-30 US US18/524,678 patent/US20240132471A1/en not_active Abandoned
-
2025
- 2025-02-25 US US19/063,141 patent/US12421209B2/en active Active
- 2025-03-26 JP JP2025051003A patent/JP2025098157A/ja active Pending
- 2025-05-16 US US19/210,925 patent/US20250276958A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240132471A1 (en) | 2024-04-25 |
| WO2022253936A1 (en) | 2022-12-08 |
| CO2023016212A2 (es) | 2023-12-11 |
| PE20240928A1 (es) | 2024-04-30 |
| EP4347571B1 (en) | 2026-04-22 |
| AU2022287224A1 (en) | 2023-09-21 |
| CA3216026A1 (en) | 2022-12-08 |
| KR20240019083A (ko) | 2024-02-14 |
| JP2024522494A (ja) | 2024-06-21 |
| BR112023025318A2 (pt) | 2024-02-27 |
| AR126053A1 (es) | 2023-09-06 |
| JP7705963B2 (ja) | 2025-07-10 |
| JP2025098157A (ja) | 2025-07-01 |
| MX2023013998A (es) | 2023-12-11 |
| CR20230566A (es) | 2024-01-22 |
| EP4347571A1 (en) | 2024-04-10 |
| US20250197370A1 (en) | 2025-06-19 |
| IL307201A (en) | 2023-11-01 |
| US12421209B2 (en) | 2025-09-23 |
| US20250276958A1 (en) | 2025-09-04 |
| TW202313577A (zh) | 2023-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023016212A2 (es) | Derivados de triazina y su uso en el tratamiento del cáncer | |
| CO2023016204A2 (es) | Inhibidores de nlrp3 | |
| ECSP20020410A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| CL2021001330A1 (es) | Nuevos compuestos heterocíclicos | |
| ECSP20021913A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| CO2023014721A2 (es) | Compuestos heterocíclicos | |
| PE20210163A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| ECSP11010880A (es) | Compuestos orgánicos | |
| CL2023000594A1 (es) | Compuestos heterocíclicos | |
| ECSP109903A (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| CO6501196A2 (es) | Compuestos antiproliferativos, cojugados de los mismos, procedimientos para éstos y uso de los mismos | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| ECSP19041050A (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| CO2023010694A2 (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
| MX2021002215A (es) | Derivados de tetrahidropiridopirimidina como moduladores de ahr. | |
| MX2023011715A (es) | Compuestos de oxoisoindolina sustituidos con piridinilo. | |
| CO2025005518A2 (es) | Derivados de triazinona como inhibidores de nlrp3 | |
| MX2022002831A (es) | Compuestos heterociclicos. | |
| UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
| CO2022000186A2 (es) | Nuevos compuestos heterocíclicos | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CL2025000126A1 (es) | Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina. | |
| CL2025000125A1 (es) | Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina. | |
| CL2020003248A1 (es) | Derivados de tetrahidrotienopiridina n-sustituidos y sus usos |